Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
More News related to ISPH
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Inspire Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
- Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results
More News related to Earnings
- RBC Upgrades Diamond Rock (DRH) to Outperform, Downgrades Hospitality Properties (HPT) to Sector Perform
- Wedbush Issues Intraday Downgrade on Warner Music (WMG)
- S&P lowers Ciena (CIEN) corporate credit rating from B+ to B
- Broadpoint.AmTech Downgraded Yingli Green Energy (YGE) to Neutral
- Macquarie Downgrades Nexen (NXY) to Neutral
Inspire Pharmaceuticals (NASDAQ: ISPH) reports Q3 loss of $0.12, 3 cents better than the analyst estimate of ($0.15). Revenue for the quarter was $25.20 million, which compares to the estimate of $23.68 million.
Related Categories
EarningsStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
